Drugs / Gefurulimab
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06677138 | Oct 2024 → Mar 2025 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06208488 | Nov 2023 → Sep 2024 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05314231 | Jun 2022 → May 2023 | proteinuria | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04920370 | Sep 2019 → Nov 2021 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06607627 | Nov 2024 → Dec 2026 expected | generalized myasthenia gravis | Alexion Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05556096 | Nov 2022 → May 2025 overdue | generalized myasthenia gravis | Alexion Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-30 | AstraZeneca | Gefurulimab demonstrates statistically significant and clinically meaningful improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) at week 26 with clinically meaningful improvement seen as early as week one in adults with gMG in PREVAIL Phase III trial astrazeneca.com ↗ |
| 2025-07-24 | AstraZeneca | Gefurulimab dual-binding nanobody demonstrated statistically significant and clinically meaningful improvement in functional activities of daily living in adults with generalised myasthenia gravis in PREVAIL Phase III trial astrazeneca.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gefurulimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06607627 ↗ |
| Known as | ALXN1720 | “A Phase 1 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Gefurulimab (ALXN1720) in Healthy Chinese Adults” NCT06677138 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5095307 ↗ |
| Route | Subcutaneous | “ALXN1720 will be administered via SC route.” NCT04920370 ↗ |